Introduction
The management of refractory idiopathic nephrotic syndrome remains a significant problem. It is a debilitating condition as infection may supervene and progression of the disease can lead to terminal renal insufficiency.
'Idiopathic' nephrotic syndrome encompasses two main forms of glomerular disease, namely minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). MCD is primarily a disease of children, which generally responds to steroids.' Patients may develop dependence on steroids and require repeated or continuous treatments, which inevitably leads to features of glucocorticoid toxicity. Resistance to steroids can occur. Alkylating agents such as cyclophosphamide and chlorambucil have also been shown to induce remission,2'3 however, the potential side effects, particularly gonadal toxicity, have limited their use. Nephrotic syndrome accompanied by lesions of FSGS carries a poor prognosis, with only 20% of cases responding to steroids.4 Up to 50% of patients with the FSGS lesion will have developed end-stage renal failure within 10 years.5
In recent years, cyclosporin A (Cy A) has been used in the treatment of nephrotic syndrome, both in adults and children.6-" Reports confirm favourable response rates in cases of steroid-dependent MCD of up to 70% and disappointing response rates of 20% in FSGS.9 This report examines the clinical experience of Cy A therapy in cases of refractory nephrotic syndrome.
Patients and methods
A retrospective study was performed to examine patients with refractory nephrotic syndrome commenced on Cy A. The patients had either become resistant to conventional treatment or had developed features of marked toxicity. All patients treated with Cy A were included in the study. Ten patients (nine male, one female) with an age range of 23 -68 years were studied. Histological examination was performed on renal biopsies from all patients. Six patients had FSGS, one patient focal global sclerosis, one patient mesangial proliferative glomerulonephritis, one patient focal proliferative glomerulonephritis and one with MCD. patients observed for 1-5 years demonstrates a very good response with a moderate dose of Cy A. The mechanism of action of Cy A in nephrotic syndrome is yet to be fully elucidated. It has been postulated that any glomerular insult (so far undefined) may lead to the production of lymphokines, including interleukin 1 and 8, which are chemotactic for macrophages and T cells, causing a brisk inflammatory response resulting in focal glomerulosclerosis and declining renal function.'2 Cy A is one of a family of cyclic peptides produced by the fungus Tolypocladium inflatus Gams. It inhibits the production and release of interleukins and gamma interferon, and is thus a potent immunosuppressor. 13 An alternative, non-immunological, mechanism for reduction of proteinuria is by alteration of intrarenal haemodynamics, as Cy A is recognized to cause intrarenal vasoconstriction, probably of the afferent arteriole, associated with a decrease in glomerular filtration rate.7 More recent work has suggested that Cy A restores charge selectivity to the glomerular basement membrane, thereby reducing the membrane permeability. '4 Cy A-related nephrotoxocity is well recognized'5 and it is important to consider the potential nephrotoxic effects, particularly in patients with already low glomerular filtration rates secondary to FSGS. In our experience, the following guidelines should be considered. The dose of Cy A should not exceed 5 mg/kg/day in adults. Blood levels should be checked one month following the introduction of treatment and, providing these are satisfactory, at two-monthly intervals thereafter. Trough levels are used and levels ranging between 50 and 150 lag/l attained. Certain drugs may lead to increased nephrotoxicity if given concomitantly with Cy A. For example, non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors and antibiotics, including erythromycin, should be used with caution.
Serum creatinine, similarly, should be measured at 1 month, then at 2-monthly intervals, and dosage of Cy A adjusted if serum creatinine increases significantly above the baseline. The drug should be avoided or discontinued in patients with a serum creatinine which is above 200 ,mol/l.
Conversely, improvements in serum creatinine may be seen in those patients obtaining a response to treatment, which permits a reduction in diuretic requirements. A trial of therapy should be discontinued ifa significant reduction in proteinuria is not achieved within 2-3 months. It is encouraging that none of the patients in the study developed severe nephrotoxicity. Similarly, only moderate elevations of blood pressure were observed.
In conclusion, Cy A is an effective and welltolerated treatment of refractory idiopathic nephrotic syndrome, including those patients with FSGS. 
